Dolby Laboratories, Inc.

DLB · XNYS

CIK 1308547fmd_1KHPHN1M3DXNCWG1NRMFX2MTAVFinance, Insurance and Real Estate · Patent Owners & LessorsTemplate: Standard

Coverage: Sep 29, 2007 to Jun 26, 2026, 71 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	1,026	1,080	1,055	1,242	1,162	1,281	1,254	1,300	1,274	1,349
Cost of revenue	109	119	128	161	146	130	141	153	140	160
Net interest income	–	–	–	–	–	3	6	28	34	15
Gross profit	917	962	927	1,081	1,015	1,151	1,112	1,147	1,133	1,189
Research and development	220	233	237	238	239	254	261	272	264	262
Selling, general and administrative	464	468	507	549	556	557	634	613	605	647
Total operating expenses	685	715	744	824	797	807	906	931	875	924
Operating income	232	247	184	257	219	344	207	216	258	265
Interest expense	0	0	0	0	0	0	0	–	–	–
Interest and investment income	6	10	19	25	13	3	7	–	–	–
Other non-operating income (expense)	4	8	13	25	21	10	9	34	54	39
Income before taxes	236	255	196	282	240	355	215	250	312	303
Income tax expense	50	48	154	27	8	37	31	48	48	47
Net income from continuing operations	186	207	42	256	232	318	184	202	264	256
Net income	186	206	42	255	231	310	184	201	262	255